Literature DB >> 10087186

Soluble, high-affinity dimers of T-cell receptors and class II major histocompatibility complexes: biochemical probes for analysis and modulation of immune responses.

M S Lebowitz1, S M O'Herrin, A R Hamad, T Fahmy, D Marguet, N C Barnes, D Pardoll, J G Bieler, J P Schneck.   

Abstract

T cell receptors (TCR) and major histocompatibility complex (MHC) molecules are integral membrane proteins that have central roles in cell-mediated immune recognition. Therefore, soluble analogs of these molecules would be useful for analyzing and possibly modulating antigen-specific immune responses. However, due to the intrinsic low-affinity and inherent solubility problems, it has been difficult to produce soluble high-affinity analogs of TCR and class II MHC molecules. This report describes a general approach which solves this intrinsic low-affinity by constructing soluble divalent analogs using IgG as a molecular scaffold. The divalent nature of the complexes increases the avidity of the chimeric molecules for cognate ligands. The generality of this approach was studied by making soluble divalent analogs of two different classes of proteins, a TCR (2C TCR2Ig) and a class II MHC (MCCI-Ek2Ig) molecule. Direct flow cytometry assays demonstrate that the divalent 2C TCR2Ig chimera retained the specificity of the native 2C TCR, while displaying increased avidity for cognate peptide/MHC ligands, resulting in a high-affinity probe capable of detecting interactions that heretofore have only been detected using surface plasmon resonance. TCR2IgG was also used in immunofluorescence studies to show ER localization of intracellular peptide-MHC complexes after peptide feeding. MCCI-Ek2Ig chimeras were able to both stain and activate an MCC-specific T cell hybridoma. Construction and expression of these two diverse heterodimers demonstrate the generality of this approach. Furthermore, the increased avidity of these soluble divalent proteins makes these chimeric molecules potentially useful in clinical settings for probing and modulating in vivo cellular responses. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10087186     DOI: 10.1006/cimm.1999.1441

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  16 in total

Review 1.  Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy.

Authors:  T L Whiteside
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

2.  Modulation of MHC binding by lateral association of TCR and coreceptor.

Authors:  Karlo Perica; Joan Glick Bieler; Michael Edidin; Jonathan Schneck
Journal:  Biophys J       Date:  2012-11-07       Impact factor: 4.033

Review 3.  MHC class II tetramers.

Authors:  Gerald T Nepom
Journal:  J Immunol       Date:  2012-03-15       Impact factor: 5.422

Review 4.  Interrogating the repertoire: broadening the scope of peptide-MHC multimer analysis.

Authors:  Mark M Davis; John D Altman; Evan W Newell
Journal:  Nat Rev Immunol       Date:  2011-07-15       Impact factor: 53.106

5.  Magnetic-activated cell sorting of TCR-engineered T cells, using tCD34 as a gene marker, but not peptide-MHC multimers, results in significant numbers of functional CD4+ and CD8+ T cells.

Authors:  Coen Govers; Cor Berrevoets; Elike Treffers-Westerlaken; Marieke Broertjes; Reno Debets
Journal:  Hum Gene Ther Methods       Date:  2012-06       Impact factor: 2.396

6.  Human cytomegalovirus-specific T-cell receptor engineered for high affinity and soluble expression using mammalian cell display.

Authors:  Ellen K Wagner; Ahlam N Qerqez; Christopher A Stevens; Annalee W Nguyen; George Delidakis; Jennifer A Maynard
Journal:  J Biol Chem       Date:  2019-02-22       Impact factor: 5.157

7.  Innovative DNA vaccine to break immune tolerance against tumor self-antigen.

Authors:  Tae Heung Kang; Chih-Ping Mao; Victor La; Alexander Chen; Chien-Fu Hung; T-C Wu
Journal:  Hum Gene Ther       Date:  2013-01-30       Impact factor: 5.695

Review 8.  From autoinflammation to autoimmunity: old and recent findings.

Authors:  Francesco Caso; Luisa Costa; Valeria Nucera; Giuseppe Barilaro; Ignazio Francesco Masala; Rossella Talotta; Paolo Caso; Raffaele Scarpa; Piercarlo Sarzi-Puttini; Fabiola Atzeni
Journal:  Clin Rheumatol       Date:  2018-07-16       Impact factor: 2.980

9.  Stabilizing mutations increase secretion of functional soluble TCR-Ig fusion proteins.

Authors:  Elin Lunde; Geir Åge Løset; Bjarne Bogen; Inger Sandlie
Journal:  BMC Biotechnol       Date:  2010-08-24       Impact factor: 2.563

10.  Nanoscale artificial antigen presenting cells for T cell immunotherapy.

Authors:  Karlo Perica; Andrés De León Medero; Malarvizhi Durai; Yen Ling Chiu; Joan Glick Bieler; Leah Sibener; Michaela Niemöller; Mario Assenmacher; Anne Richter; Michael Edidin; Mathias Oelke; Jonathan Schneck
Journal:  Nanomedicine       Date:  2013-07-24       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.